|
You are here:
Manager factsheet
|
|
Manager profile
Linden is a Senior Fund Manager at Candriam, managing the Candriam Equities L Biotechnology and Candriam Equities L Oncology Impact strategies since 1 February 2024. Prior to joining Candriam, she worked at AXA Investment Managers where she was the lead, AXA IM Framlington Biotech Fund as well as the Head of their Healthcare Franchise and Member of the UK Executive Committee. She is a seasoned professional with over two decades of buy-side and sell-side experience as one of the early specialists in the biotechnology sector. Linden started her career at Goldman Sachs in 2003, establishing a deep technical expertise in the healthcare space, before moving on to a biotech hedge fund at start-up stage and subsequently to AXA Investment Managers in 2011. Linden holds a BS (Hons) in Medical Microbiology from the University of Edinburgh. She is a CFA Charterholder since 2011.
|
|
|
 | |  |
|
|
|
 |
Annualised total return over 25.3 years |
+8.7% |
 |
|
| |
1 year |
3 years |
5 years |
7 years |
10 years |
| Linden Thomson |
-9.8 |
0.9 |
34.5 |
55.1 |
53.2 |
Peer Group Composite
|
-8.5 |
-10.5 |
10.9 |
32.0 |
42.1 |
| Over / Under |
-1.3 |
11.4 |
23.6 |
23.1 |
11.1 |
|
|
|
 |
|
 |
|
|
|
Total return for Linden Thomson
|
|
|
Discrete calendar year performance : Linden Thomson
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.
You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser. Close